Differential Antagonism of Activin, Myostatin and Growth and Differentiation Factor 11 by Wild-Type and Mutant Follistatin
- 5 June 2008
- journal article
- other
- Published by The Endocrine Society in Endocrinology
- Vol. 149 (9) , 4589-4595
- https://doi.org/10.1210/en.2008-0259
Abstract
Follistatin binds and neutralizes members of the TGFβ superfamily including activin, myostatin, and growth and differentiation factor 11 (GDF11). Crystal structure analysis of the follistatin-activin complex revealed extensive contacts between follistatin domain (FSD)-2 and activin that was critical for the high-affinity interaction. However, it remained unknown whether follistatin residues involved with myostatin and GDF11 binding were distinct from those involved with activin binding. If so, this would allow development of myostatin antagonists that would not inhibit activin actions, a desirable feature for development of myostatin antagonists for treatment of muscle-wasting disorders. We tested this hypothesis with our panel of point and domain swapping follistatin mutants using competitive binding analyses and in vitro bioassays. Our results demonstrate that activin binding and neutralization are mediated primarily by FSD2, whereas myostatin binding is more dependent on FSD1, such that deletion of FSD2 or adding an extra FSD1 in place of FSD2 creates myostatin antagonists with vastly reduced activin antagonism. However, these mutants also bind GDF11, indicating that further analysis is required for creation of myostatin antagonists that will not affect GDF11 activity that could potentially elicit GDF11-induced side effects in vivo.Keywords
This publication has 29 references indexed in Scilit:
- Therapeutic approaches for muscle wasting disordersPharmacology & Therapeutics, 2007
- FSTL3 deletion reveals roles for TGF-β family ligands in glucose and fat homeostasis in adultsProceedings of the National Academy of Sciences, 2007
- REGULATION OF MUSCLE MASS BY MYOSTATINAnnual Review of Cell and Developmental Biology, 2004
- Activin A and follistatin in systemic inflammationMolecular and Cellular Endocrinology, 2004
- Activin: an important regulator of wound repair, fibrosis, and neuroprotectionMolecular and Cellular Endocrinology, 2004
- Activins, Myostatin and Related TGF-β Family Members as Novel Therapeutic Targets for Endocrine, Metabolic and Immune DisordersCurrent Drug Target - Immune, Endocrine & Metabolic Disorders, 2004
- Follistatin: Essential Role for the N-terminal Domain in Activin Binding and NeutralizationJournal of Biological Chemistry, 2001
- Regulation of skeletal muscle mass in mice by a new TGF-p superfamily memberNature, 1997
- Osteoblasts Express Types I and II Activin Receptors During Early Intramembranous and Endochondral Bone FormationJournal of Bone and Mineral Research, 1997
- Functional analysis of activins during mammalian developmentNature, 1995